A Phase 2 interventional study of Sacituzumab Govitecan-hziy in Metastatic Solid Tumor, sponsored by Gilead Sciences. Active, not recruiting at 65 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 2,054 studies in Neoplasm Metastasis with a site in United States — 346 open to participants now, 542 under way, 58 of them phase 3. Neoplasm Metastasis · United States.
Among the 2,054 studies in Neoplasm Metastasis with a site in United States, this one is the 273rd largest by enrollment of the 1,863 interventional ones that give a count, is one of 90 that started in 2019, is one of 566 in phase 2, reaches primary completion later than 49 of the 540 other live ones, and was the 1,332nd registered.
4,045 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.
Browse Neoplasm Metastasis studies →346 of the 2,054 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
SystImmune Inc. · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
LTZ Therapeutics, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
2,054 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 976 · Phase 2 855 · Phase 3 186 · Phase 4 15
First in 1978; this study’s year is marked. 90 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 227 is above the median of 50 across 3,271 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 43 across the 1,863 interventional studies, 100 across the 139 observational. Of the 1,391 that completed or were terminated, 602 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
925 of 2,054 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 2 studies filed under Neoplasm Metastasis — fewer than ten, so there is no comparison to draw.
203 of the studies in Neoplasm Metastasis with a site in United States that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03525873Phase 3M.D. Anderson Cancer CenterA Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy | 2026-12-31 |
| NCT03927885Phase 3M.D. Anderson Cancer CenterOpen Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer | 2026-12-31 |
| NCT06947928Phase 3TuHURA Biosciences, Inc.Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | 2027-03-31 |
| NCT06506955Phase 3Taiho Oncology, Inc.Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy. | 2027-04 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
Add all 203 to your calendar (.ics) → With an account.
Among the 2,054 studies in Neoplasm Metastasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with metastatic (cancer that has spread) solid tumors.
Key Inclusion Criteria:
Individuals with the following documented (M1, Stage IV) or locally advanced solid tumors
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Based on protocol amendment 1, participants with non-small cell lung cancer (NSCLC) subtypes such as adenocarcinoma and SCC with high trophoblast cell-surface antigen 2 (Trop-2) expression will receive sacituzumab govitecan-hziy (SG) 10 mg/kg of body weight, administered as a slow intravenous (IV) infusion on Days 1 and 8 of a 21-day treatment cycle until progression of disease, unacceptable toxicity, study withdrawal, death, or another treatment discontinuation criteria will be met.
Drug: Sacituzumab Govitecan-hziy
Based on protocol amendment 2 or 3, participants with NSCLC subtype of adenocarcinoma with or without high Trop-2 expression will receive SG 10 mg/kg of body weight, administered as a slow IV infusion on Days 1 and 8 of a 21-day treatment cycle until progression of disease, unacceptable toxicity, study withdrawal, death, or another treatment discontinuation criteria will be met.
Drug: Sacituzumab Govitecan-hziy
Based on protocol amendment 2 or 3, participants with NSCLC subtype of SCC with or without high Trop-2 expression will receive SG 10 mg/kg of body weight, administered as a slow IV infusion on Days 1 and 8 of a 21-day treatment cycle until progression of disease, unacceptable toxicity, study withdrawal, death, or another treatment discontinuation criteria will be met.
Drug: Sacituzumab Govitecan-hziy
Participants with HNSCC will receive SG 10 mg/kg of body weight, administered as a slow IV infusion on Days 1 and 8 of a 21-day treatment cycle until progression of disease, unacceptable toxicity, study withdrawal, death, or another treatment discontinuation criteria will be met.
Drug: Sacituzumab Govitecan-hziy
Participants with EC will receive SG 10 mg/kg of body weight, administered as a slow IV infusion on Days 1 and 8 of a 21-day treatment cycle until progression of disease, unacceptable toxicity, study withdrawal, death, or another treatment discontinuation criteria will be met.
Drug: Sacituzumab Govitecan-hziy
Participants with ES-SCLC will receive SG 10 mg/kg of body weight, administered as a slow IV infusion on Days 1 and 8 of a 21-day treatment cycle until progression of disease, unacceptable toxicity, study withdrawal, death, or another treatment discontinuation criteria will be met.
Drug: Sacituzumab Govitecan-hziy
Administered intravenously
Also known as: IMMU-132, GS-0132
Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator's Assessment
ORR was defined as the percentage of participants who had the best overall response of either complete response (CR) or partial response (PR). Responses are based on the investigator-assessed tumor response using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) criteria for each histologic cohort. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: \>30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. The ORR rate was calculated with a two-sided exact 95% CI using the Clopper-Pearson method. Percentages are rounded off.
Time frame: Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years
ORR According to RECIST 1.1 by Blinded Independent Central Review (BICR) Assessment
ORR was defined as the percentage of participants who had the best overall response of either CR or PR. Responses are based on BICR assessment using RECIST 1.1 criteria for each histologic cohort. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: \>30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. The ORR rate was calculated with a two-sided exact 95% CI using the Clopper-Pearson method.
Time frame: Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years
Duration of Response (DOR) According to RECIST 1.1 by BICR Assessment
DOR was the date of the first evaluation showing documented response, either PR or CR, to date of the first progression of disease (PD) or death from any cause,whichever comes first. Response are according to RECIST 1.1 by BICR for each histological cohort. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal;PR: \>30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Disease progression was defined as an increase of \>20% in the sum of diameters of target lesions, taking as reference the smallest sum on study(this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of more than 5 mm or the appearance of ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions. DOR was estimated using Kaplan-Meier estimate. The 95% CI was computed by Brookmeyer-Crowley method.
Time frame: Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years
Clinical Benefit Rate (CBR) According to RECIST 1.1 by BICR Assessment
CBR was percentage of participants with best overall response of CR, PR,or durable stable disease (SD) (SD ≥ 6 months after first dose). Responses are according to RECIST 1.1 by BICR.CR: Disappearance of all target and non-target lesions;\& normalization of tumor marker levels initially above upper limits of normal;PR:\>30% decrease in sum of LD of target lesions, taking as reference the baseline sum LD. SD:Neither sufficient shrinkage for PR nor sufficient increase for PD, taking reference of smallest sum LD since treatment started or ≥ 1 non-target lesions with maintenance of tumor marker level above normal limits.PD: Increase of \>20% in sum of diameters of target lesions, taking reference of smallest sum(this includes baseline sum if smallest on study), the sum must also demonstrate an absolute increase of more than 5 mm or of ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions. Two-sided CI was based on Clopper-Pearson method.
Time frame: Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years
Progression-free Survival (PFS) According to RECIST 1.1 by BICR Assessment
PFS was defined as the time from the first dose until objective tumor progression or death from any cause, whichever comes first. Responses are according to RECIST 1.1 by BICR. Disease progression was defined as an increase of \>20% in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of more than 5 mm or the appearance ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions. PFS was estimated using Kaplan-Meier estimate. The 95% CI for median was computed by Brookmeyer-Crowley method.
Time frame: Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years
DOR According to RECIST 1.1 by Investigator's Assessment
DOR was the date of the first evaluation showing documented response, either PR or CR, to date of the first PD or death from any cause, whichever comes first. Responses are based on investigator-assessed tumor response by RECIST 1.1 criteria for each histological cohort.CR:Disappearance of all target and non-target lesions;and normalization of tumor marker levels initially above upper limits of normal;PR:\>30% decrease in the sum of the LD of target lesions,taking as reference the baseline sum LD. Disease progression was defined as increase of \>20% in sum of diameters of target lesions, taking as reference the smallest sum on study(this includes the baseline sum if that is the smallest on study).In addition, the sum must also demonstrate an absolute increase of more than 5 mm or the appearance of ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions. DOR was estimated using Kaplan-Meier estimate. The 95% CI was computed by Brookmeyer-Crowley method.
Time frame: Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years
CBR According to RECIST 1.1 by Investigator's Assessment
CBR was the percentage of participants with the best overall response of CR, PR,or durable SD (SD ≥ 6 months after first dose) by investigator-assessed tumor response using RECIST 1.1 criteria.CR:Disappearance of all target and non-target lesions;\& normalization of tumor marker levels initially above upper limits of normal;PR:\>30% decrease in sum of LD of target lesions,taking as reference the baseline sum LD. SD:Neither sufficient shrinkage for PR nor sufficient increase for PD,taking reference of smallest sum LD since treatment started or ≥ 1 non-target lesions with maintenance of tumor marker level above normal limits.PD: Increase of \>20% in sum of diameters of target lesions,taking reference of smallest sum(this includes baseline sum if smallest on study),the sum must also demonstrate an absolute increase of more than 5 mm or of ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions.Two-sided CI was based on Clopper-Pearson method.
Time frame: Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years
PFS According to RECIST 1.1 by Investigator's Assessment
PFS was defined as the time from the first dose until objective tumor progression or death from any cause, whichever comes first. Responses are based on the investigator-assessed tumor response using RECIST 1.1 criteria. Disease progression was defined as an increase of \>20% in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of more than 5 mm or the appearance ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions. PFS was estimated using Kaplan-Meier estimate. The 95% CI for median was computed by Brookmeyer-Crowley method.
Time frame: Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years
Overall Survival (OS)
OS was defined as the interval from the first dose date of drug to death from any cause. OS was estimated using Kaplan-Meier estimate. The 95% CI for median was computed by Brookmeyer-Crowley method.
Time frame: Cohort 1: Up to 5.3 years; Cohort 2: Up to 3.4 years; Cohort 3: Up to 3.3 years; Cohort 4: Up to 2.5 years
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
A TEAE was defined as any AE with an onset date on or after the study drug start date and no later than 30 days after last dose of study drug or the day before initiation of subsequent therapy, whichever comes first.
Time frame: Up to 7.2 years
Percentage of Participants Experiencing Clinically Significant Laboratory Abnormalities
A treatment-emergent laboratory abnormality was defined as any value that increased at least 1 toxicity grade from baseline during the treatment-emergent period.
Time frame: Up to 7.2 years
Pharmacokinetic (PK) Parameter: Cmax of Total SN-38
Cmax was defined as the maximum observed concentration of total SN-38 (the active metabolite of sacituzumab Govitecan-hziy). Cycle length=21 days.
Time frame: Cohort 1: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29,35,41,47; Cohort 2: Post dose: Day 1 of Cycles 1,2,3,7,11,17; Cohort 3: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29,35,41,47,53; Cohort 4: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29
PK Parameter: Cmax of Free SN-38
Cmax was defined as the maximum observed concentration of free SN-38 (the active metabolite of sacituzumab Govitecan-hziy). Cycle length=21 days.
Time frame: Cohort 1: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29,35,41,47; Cohort 2: Post dose: Day 1 of Cycles 1,2,3,7,11,17; Cohort 3: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29,35,41,47,53; Cohort 4: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29
PK Parameter: Cmax of Total Antibody
Cmax was defined as the maximum observed concentration of total antibody of SG \[hRS7 immunoglobulin (IgG) and hRS7-SN-38\]. Cycle length=21 days.
Time frame: Cohort 1: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29,35,41,47; Cohort 2: Post dose: Day 1 of Cycles 1,2,3,7,11,17; Cohort 3: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29,35,41,47,53; Cohort 4: Post dose: Day 1 of Cycles 1,2,3,7,11,17,23,29
PK Parameter: Ctrough of Total SN-38
Ctrough was defined as concentration at the end of the dosing interval of total SN-38 (the active metabolite of sacituzumab Govitecan-hziy). Cycle length=21 days; C=Cohort; D=Day; EOT=End of Treatment; PD=predose; SFU=Safety Follow-up (up to 30 days after EOT date)
Time frame: C1:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,EOT(Upto 38.7months)&SFU;C2:PD,D1:Cycles1,2,3,7,11,17,EOT(Upto 12.3months)&SFU;C3:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,53,EOT(Upto 40.0months)&SFU;C4:PD,D1:Cycles1,2,3,7,11,17,23,29,EOT(Upto 29.3months)&SFU
PK Parameter: Ctrough of Free SN-38
Ctrough was defined as concentration at the end of the dosing interval of free SN-38 (the active metabolite of sacituzumab Govitecan-hziy). Cycle length=21 days; C=Cohort; D=Day; EOT=End of Treatment; PD=predose; SFU=Safety Follow-up (up to 30 days after EOT date)
Time frame: C1:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,EOT(Upto 38.7months)&SFU;C2:PD,D1:Cycles1,2,3,7,11,17,EOT(Upto 12.3months)&SFU;C3:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,53,EOT(Upto 40.0months)&SFU;C4:PD,D1:Cycles1,2,3,7,11,17,23,29,EOT(Upto 29.3months)&SFU
PK Parameter: Ctrough of Total Antibody
Ctrough was defined as concentration at the end of the dosing interval of total antibody of SG \[hRS7 immunoglobulin (IgG) and hRS7-SN-38\]. Cycle length=21 days; C=Cohort; D=Day; EOT=End of Treatment; PD=predose; SFU=Safety Follow-up (up to 30 days after EOT date)
Time frame: C1:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,EOT(Upto 38.7months)&SFU;C2:PD,D1:Cycles1,2,3,7,11,17,EOT(Upto 12.3months)&SFU;C3:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,53,EOT(Upto 40.0months)&SFU;C4:PD,D1:Cycles1,2,3,7,11,17,23,29,EOT(Upto 29.3months)&SFU
Percentage of Participants With Positive Anti-SG Antibodies
Cycle length=21 days; C=Cohort; D=Day; EOT=End of Treatment; PD=predose; SFU=Safety Follow-up (up to 30 days after EOT date)
Time frame: C1:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,EOT(Upto 38.7months)&SFU;C2:PD,D1:Cycles1,2,3,7,11,17,EOT(Upto 12.3months)&SFU;C3:PD,D1:Cycles1,2,3,7,11,17,23,29,35,41,47,53,EOT(Upto 40.0months)&SFU;C4:PD,D1:Cycles1,2,3,7,11,17,23,29,EOT(Upto 29.3months)&SFU
Participants were enrolled at study sites in the United States, France, Australia, Hong Kong, Spain, Taiwan, Canada, and Belgium.
| Milestone | Cohort 1 Group 1: NSCLC [Adenocarcinoma + Squamous Cell Carcinoma (SCC)] | Cohort 1 Group 2: NSCLC (Adenocarcinoma) | Cohort 1 Group 3: NSCLC (SCC) | Cohort 2: Head And Neck Squamous Cell Carcinoma (HNSCC) | Cohort 3: Endometrial Cancer (EC) | Cohort 4: Extensive-Stage Small Cell Lung Cancer (ES-SCLC) |
|---|---|---|---|---|---|---|
| Started | 31 | 34 | 31 | 43 | 41 | 43 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 31 | 34 | 31 | 43 | 41 | 43 |
| Withdrew: Death | 14 | 23 | 25 | 31 | 28 | 32 |
| Withdrew: Still on study | 0 | 6 | 2 | 4 | 7 | 8 |
| Withdrew: Reason not specified | 16 | 3 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 3 | 7 | 4 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 2 | 0 |
ORR was defined as the percentage of participants who had the best overall response of either complete response (CR) or partial response (PR). Responses are based on the investigator-assessed tumor response using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) criteria for each histologic cohort. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: \>30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. The ORR rate was calculated with a two-sided exact 95% CI using the Clopper-Pearson method. Percentages are rounded off.
| percentage of participants | Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | Cohort 1 Group 2: NSCLC (Adenocarcinoma) | Cohort 1 Group 3: NSCLC (SCC) | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by Investigator's Assessment | 12.9 (3.6 to 29.8) | 5.9 (0.7 to 19.7) | 6.5 (0.8 to 21.4) | 16.3 (6.8 to 30.7) | 26.8 (14.2 to 42.9) | 44.2 (29.1 to 60.1) |
ORR was defined as the percentage of participants who had the best overall response of either CR or PR. Responses are based on BICR assessment using RECIST 1.1 criteria for each histologic cohort. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal; PR: \>30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. The ORR rate was calculated with a two-sided exact 95% CI using the Clopper-Pearson method.
| percentage of participants | Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | Cohort 1 Group 2: NSCLC (Adenocarcinoma) | Cohort 1 Group 3: NSCLC (SCC) | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC |
|---|---|---|---|---|---|---|
| ORR According to RECIST 1.1 by Blinded Independent Central Review (BICR) Assessment | 3.2 (0.1 to 16.7) | 8.8 (1.9 to 23.7) | 16.1 (5.5 to 33.7) | 18.6 (8.4 to 33.4) | 24.4 (12.4 to 40.3) | 44.2 (29.1 to 60.1) |
DOR was the date of the first evaluation showing documented response, either PR or CR, to date of the first progression of disease (PD) or death from any cause,whichever comes first. Response are according to RECIST 1.1 by BICR for each histological cohort. CR: Disappearance of all target and non-target lesions; and normalization of tumor marker levels initially above upper limits of normal;PR: \>30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Disease progression was defined as an increase of \>20% in the sum of diameters of target lesions, taking as reference the smallest sum on study(this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of more than 5 mm or the appearance of ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions. DOR was estimated using Kaplan-Meier estimate. The 95% CI was computed by Brookmeyer-Crowley method.
| months | Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | Cohort 1 Group 2: NSCLC (Adenocarcinoma) | Cohort 1 Group 3: NSCLC (SCC) | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC |
|---|---|---|---|---|---|---|
| Duration of Response (DOR) According to RECIST 1.1 by BICR Assessment | 2.86 (NA to NA) | 22.08 (10.55 to NA) | 4.70 (2.10 to NA) | 8.67 (2.83 to NA) | 16.00 (2.76 to NA) | 6.01 (2.92 to 10.22) |
CBR was percentage of participants with best overall response of CR, PR,or durable stable disease (SD) (SD ≥ 6 months after first dose). Responses are according to RECIST 1.1 by BICR.CR: Disappearance of all target and non-target lesions;\& normalization of tumor marker levels initially above upper limits of normal;PR:\>30% decrease in sum of LD of target lesions, taking as reference the baseline sum LD. SD:Neither sufficient shrinkage for PR nor sufficient increase for PD, taking reference of smallest sum LD since treatment started or ≥ 1 non-target lesions with maintenance of tumor marker level above normal limits.PD: Increase of \>20% in sum of diameters of target lesions, taking reference of smallest sum(this includes baseline sum if smallest on study), the sum must also demonstrate an absolute increase of more than 5 mm or of ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions. Two-sided CI was based on Clopper-Pearson method.
| percentage of participants | Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | Cohort 1 Group 2: NSCLC (Adenocarcinoma) | Cohort 1 Group 3: NSCLC (SCC) | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC |
|---|---|---|---|---|---|---|
| Clinical Benefit Rate (CBR) According to RECIST 1.1 by BICR Assessment | 29.0 (14.2 to 48.0) | 23.5 (10.7 to 41.2) | 19.4 (7.5 to 37.5) | 27.9 (15.3 to 43.7) | 39.0 (24.2 to 55.5) | 46.5 (31.2 to 62.3) |
PFS was defined as the time from the first dose until objective tumor progression or death from any cause, whichever comes first. Responses are according to RECIST 1.1 by BICR. Disease progression was defined as an increase of \>20% in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of more than 5 mm or the appearance ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions. PFS was estimated using Kaplan-Meier estimate. The 95% CI for median was computed by Brookmeyer-Crowley method.
| months | Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | Cohort 1 Group 2: NSCLC (Adenocarcinoma) | Cohort 1 Group 3: NSCLC (SCC) | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC |
|---|---|---|---|---|---|---|
| Progression-free Survival (PFS) According to RECIST 1.1 by BICR Assessment | 4.11 (2.50 to 7.52) | 4.24 (2.27 to 7.59) | 2.73 (1.41 to 5.49) | 3.25 (1.74 to 6.47) | 5.55 (2.79 to 9.59) | 4.40 (3.19 to 6.67) |
DOR was the date of the first evaluation showing documented response, either PR or CR, to date of the first PD or death from any cause, whichever comes first. Responses are based on investigator-assessed tumor response by RECIST 1.1 criteria for each histological cohort.CR:Disappearance of all target and non-target lesions;and normalization of tumor marker levels initially above upper limits of normal;PR:\>30% decrease in the sum of the LD of target lesions,taking as reference the baseline sum LD. Disease progression was defined as increase of \>20% in sum of diameters of target lesions, taking as reference the smallest sum on study(this includes the baseline sum if that is the smallest on study).In addition, the sum must also demonstrate an absolute increase of more than 5 mm or the appearance of ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions. DOR was estimated using Kaplan-Meier estimate. The 95% CI was computed by Brookmeyer-Crowley method.
| months | Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | Cohort 1 Group 2: NSCLC (Adenocarcinoma) | Cohort 1 Group 3: NSCLC (SCC) | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC |
|---|---|---|---|---|---|---|
| DOR According to RECIST 1.1 by Investigator's Assessment | 8.56 (6.41 to NA) | 21.09 (11.10 to NA) | 7.87 (6.05 to NA) | 4.21 (2.60 to 8.67) | 9.92 (2.79 to NA) | 6.31 (3.52 to 10.22) |
CBR was the percentage of participants with the best overall response of CR, PR,or durable SD (SD ≥ 6 months after first dose) by investigator-assessed tumor response using RECIST 1.1 criteria.CR:Disappearance of all target and non-target lesions;\& normalization of tumor marker levels initially above upper limits of normal;PR:\>30% decrease in sum of LD of target lesions,taking as reference the baseline sum LD. SD:Neither sufficient shrinkage for PR nor sufficient increase for PD,taking reference of smallest sum LD since treatment started or ≥ 1 non-target lesions with maintenance of tumor marker level above normal limits.PD: Increase of \>20% in sum of diameters of target lesions,taking reference of smallest sum(this includes baseline sum if smallest on study),the sum must also demonstrate an absolute increase of more than 5 mm or of ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions.Two-sided CI was based on Clopper-Pearson method.
| percentage of participants | Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | Cohort 1 Group 2: NSCLC (Adenocarcinoma) | Cohort 1 Group 3: NSCLC (SCC) | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC |
|---|---|---|---|---|---|---|
| CBR According to RECIST 1.1 by Investigator's Assessment | 32.3 (16.7 to 51.4) | 20.6 (8.7 to 37.9) | 16.1 (5.5 to 33.7) | 30.2 (17.2 to 46.1) | 41.5 (26.3 to 57.9) | 48.8 (33.3 to 64.5) |
PFS was defined as the time from the first dose until objective tumor progression or death from any cause, whichever comes first. Responses are based on the investigator-assessed tumor response using RECIST 1.1 criteria. Disease progression was defined as an increase of \>20% in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition, the sum must also demonstrate an absolute increase of more than 5 mm or the appearance ≥ 1 new non-target lesions and/or unequivocal progression of existing non-target lesions. PFS was estimated using Kaplan-Meier estimate. The 95% CI for median was computed by Brookmeyer-Crowley method.
| months | Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | Cohort 1 Group 2: NSCLC (Adenocarcinoma) | Cohort 1 Group 3: NSCLC (SCC) | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC |
|---|---|---|---|---|---|---|
| PFS According to RECIST 1.1 by Investigator's Assessment | 2.79 (1.48 to 7.82) | 3.78 (1.41 to 5.65) | 2.56 (1.41 to 5.49) | 4.14 (1.71 to 5.78) | 4.96 (2.76 to 9.82) | 4.40 (3.81 to 6.11) |
OS was defined as the interval from the first dose date of drug to death from any cause. OS was estimated using Kaplan-Meier estimate. The 95% CI for median was computed by Brookmeyer-Crowley method.
| months | Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | Cohort 1 Group 2: NSCLC (Adenocarcinoma) | Cohort 1 Group 3: NSCLC (SCC) | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC |
|---|---|---|---|---|---|---|
| Overall Survival (OS) | 14.26 (4.34 to 23.72) | 11.02 (4.24 to 20.47) | 7.29 (5.16 to 10.22) | 8.97 (7.52 to 12.22) | 14.95 (5.88 to 21.42) | 11.73 (6.57 to 14.72) |
A TEAE was defined as any AE with an onset date on or after the study drug start date and no later than 30 days after last dose of study drug or the day before initiation of subsequent therapy, whichever comes first.
Results for this outcome have not been posted.
A treatment-emergent laboratory abnormality was defined as any value that increased at least 1 toxicity grade from baseline during the treatment-emergent period.
Results for this outcome have not been posted.
Cmax was defined as the maximum observed concentration of total SN-38 (the active metabolite of sacituzumab Govitecan-hziy). Cycle length=21 days.
| nanograms per milliliter (ng/mL) | Cohort 1: NSCLC | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC |
|---|---|---|---|---|
| Cycle 1 Day 1 | 4790 ± 1170 | 4410 ± 734 | 4920 ± 1060 | 4670 ± 738 |
| Cycle 2 Day 1 | 4420 ± 1010 | 4210 ± 807 | 4640 ± 1840 | 4330 ± 760 |
| Cycle 3 Day 1 | 4280 ± 1420 | 3930 ± 1080 | 4440 ± 1130 | 4150 ± 1040 |
| Cycle 7 Day 1 | 4220 ± 949 | 3750 ± 1090 | 4430 ± 915 | 4210 ± 1160 |
| Cycle 11 Day 1 | 4210 ± 1200 | 4720 ± 1210 | 4390 ± 1030 | 4250 ± 1390 |
| Cycle 17 Day 1 | 4620 ± 849 | 4700 ± 647 | 4970 ± 922 | 5510 ± 783 |
| Cycle 23 Day 1 | 5140 ± 1090 | — | 4880 ± 1050 | 5420 ± 912 |
| Cycle 29 Day 1 | 4580 ± 679 | — | 4720 ± 499 | 5520 ± 424 |
| Cycle 35 Day 1 | 4360 ± 1100 | — | 4110 ± 898 | — |
| Cycle 41 Day 1 | 5230 ± 1150 | — | 5450 ± NA | — |
| Cycle 47 Day 1 | 4260 ± 1610 | — | 4580 ± NA | — |
| Cycle 53 Day 1 | — | — | 5210 ± NA | — |
Cmax was defined as the maximum observed concentration of free SN-38 (the active metabolite of sacituzumab Govitecan-hziy). Cycle length=21 days.
| ng/mL | Cohort 1: NSCLC | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC |
|---|---|---|---|---|
| Cycle 1 Day 1 | 65.4 ± 23.5 | 200 ± 386 | 94.5 ± 143 | 78.5 ± 60.6 |
| Cycle 2 Day 1 | 67.0 ± 40.2 | 94.9 ± 160 | 70.2 ± 69.1 | 87.1 ± 65.8 |
| Cycle 3 Day 1 | 107 ± 277 | 46.8 ± 17.2 | 62.5 ± 41.1 | 74.4 ± 75.9 |
| Cycle 7 Day 1 | 64.6 ± 26.1 | 70.7 ± 50.1 | 63.8 ± 57.2 | 78.7 ± 63.3 |
| Cycle 11 Day 1 | 54.6 ± 11.1 | 57.1 ± 29.8 | 59.3 ± 54.0 | 51.6 ± 25.2 |
| Cycle 17 Day 1 | 56.6 ± 11.0 | 52.1 ± 18.1 | 73.3 ± 37.6 | 74.6 ± 35.2 |
| Cycle 23 Day 1 | 72.8 ± 35.9 | — | 57.3 ± 21.2 | 53.0 ± 17.3 |
| Cycle 29 Day 1 | 67.0 ± 23.0 | — | 158 ± 140 | 170 ± 138 |
| Cycle 35 Day 1 | 69.4 ± 51.1 | — | 90.4 ± 81.3 | — |
| Cycle 41 Day 1 | 76.1 ± 32.3 | — | 158 ± NA | — |
| Cycle 47 Day 1 | 41.9 ± 8.77 | — | 369 ± NA | — |
| Cycle 53 Day 1 | — | — | 239 ± NA | — |
Cmax was defined as the maximum observed concentration of total antibody of SG \[hRS7 immunoglobulin (IgG) and hRS7-SN-38\]. Cycle length=21 days.
| ng/mL | Cohort 1: NSCLC | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC |
|---|---|---|---|---|
| Cycle 1 Day 1 | 232000 ± 79200 | 209000 ± 54700 | 249000 ± 77700 | 222000 ± 49400 |
| Cycle 2 Day 1 | 245000 ± 79700 | 234000 ± 98700 | 258000 ± 114000 | 231000 ± 73000 |
| Cycle 3 Day 1 | 260000 ± 108000 | 234000 ± 80600 | 294000 ± 114000 | 240000 ± 82100 |
| Cycle 7 Day 1 | 272000 ± 139000 | 245000 ± 108000 | 305000 ± 116000 | 260000 ± 107000 |
| Cycle 11 Day 1 | 287000 ± 120000 | 330000 ± 114000 | 339000 ± 123000 | 315000 ± 132000 |
| Cycle 17 Day 1 | 313000 ± 95800 | 369000 ± 179000 | 338000 ± 127000 | 380000 ± 128000 |
| Cycle 23 Day 1 | 356000 ± 145000 | — | 313000 ± 104000 | 473000 ± 45300 |
| Cycle 29 Day 1 | 227000 ± 218000 | — | 360000 ± 108000 | 506000 ± NA |
| Cycle 35 Day 1 | 304000 ± 63700 | — | 286000 ± 137000 | — |
| Cycle 41 Day 1 | 282000 ± 66500 | — | 434000 ± NA | — |
| Cycle 47 Day 1 | 257000 ± 47400 | — | 283000 ± NA | — |
| Cycle 53 Day 1 | — | — | 281000 ± NA | — |
Ctrough was defined as concentration at the end of the dosing interval of total SN-38 (the active metabolite of sacituzumab Govitecan-hziy). Cycle length=21 days; C=Cohort; D=Day; EOT=End of Treatment; PD=predose; SFU=Safety Follow-up (up to 30 days after EOT date)
| ng/mL | Cohort 1: NSCLC | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC |
|---|---|---|---|---|
| Cycle 1 Day 1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Cycle 2 Day 1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Cycle 3 Day 1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Cycle 7 Day 1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Cycle 11 Day 1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Cycle 17 Day 1 | 10.1 ± 4.05 | 9.78 ± 2.66 | 10.8 ± 5.27 | 9.69 ± 3.46 |
| Cycle 23 Day 1 | NA ± NA | — | NA ± NA | 10.1 ± 2.99 |
| Cycle 29 Day 1 | NA ± NA | — | 21.0 ± 24.4 | 6.68 ± NA |
| Cycle 35 Day 1 | 7.00 ± 1.78 | — | NA ± NA | — |
| Cycle 41 Day 1 | NA ± NA | — | 6.61 ± NA | — |
| Cycle 47 Day 1 | NA ± NA | — | 6.12 ± NA | — |
| Cycle 53 Day 1 | — | — | 7.55 ± NA | — |
| EOT | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| SFU | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
Ctrough was defined as concentration at the end of the dosing interval of free SN-38 (the active metabolite of sacituzumab Govitecan-hziy). Cycle length=21 days; C=Cohort; D=Day; EOT=End of Treatment; PD=predose; SFU=Safety Follow-up (up to 30 days after EOT date)
| ng/mL | Cohort 1: NSCLC | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC |
|---|---|---|---|---|
| Cycle 1 Day 1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Cycle 2 Day 1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Cycle 3 Day 1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Cycle 7 Day 1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Cycle 11 Day 1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Cycle 17 Day 1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Cycle 23 Day 1 | NA ± NA | — | NA ± NA | NA ± NA |
| Cycle 29 Day 1 | NA ± NA | — | NA ± NA | NA ± NA |
| Cycle 35 Day 1 | NA ± NA | — | NA ± NA | — |
| Cycle 41 Day 1 | NA ± NA | — | NA ± NA | — |
| Cycle 47 Day 1 | NA ± NA | — | NA ± NA | — |
| Cycle 53 Day 1 | — | — | NA ± NA | — |
| EOT | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| SFU | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
Ctrough was defined as concentration at the end of the dosing interval of total antibody of SG \[hRS7 immunoglobulin (IgG) and hRS7-SN-38\]. Cycle length=21 days; C=Cohort; D=Day; EOT=End of Treatment; PD=predose; SFU=Safety Follow-up (up to 30 days after EOT date)
| ng/mL | Cohort 1: NSCLC | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC |
|---|---|---|---|---|
| Cycle 1 Day 1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Cycle 2 Day 1 | 35200 ± 24900 | 52600 ± 44300 | 46200 ± 36100 | 36000 ± 26500 |
| Cycle 3 Day 1 | 79500 ± 58200 | 69000 ± 40700 | 73500 ± 49100 | 59500 ± 49600 |
| Cycle 7 Day 1 | 89600 ± 80400 | 70200 ± 51600 | 107000 ± 60800 | 65200 ± 44800 |
| Cycle 11 Day 1 | 97500 ± 77400 | 169000 ± 67700 | 86900 ± 46800 | 81600 ± 44300 |
| Cycle 17 Day 1 | 126000 ± 61500 | 124000 ± 57700 | 104000 ± 58800 | 107000 ± 20400 |
| Cycle 23 Day 1 | 80700 ± 56000 | — | 58200 ± 41700 | 97300 ± 13800 |
| Cycle 29 Day 1 | 83400 ± 42200 | — | 71100 ± 4190082800 | 86100 ± NA |
| Cycle 35 Day 1 | 94800 ± 17900 | — | 82800 ± 105000 | — |
| Cycle 41 Day 1 | 39200 ± 51600 | — | 2660 ± NA | — |
| Cycle 47 Day 1 | 42100 ± 56200 | — | 2670 ± NA | — |
| Cycle 53 Day 1 | — | — | 77200 ± NA | — |
| EOT | 54800 ± 43100 | 64600 ± 51500 | 62100 ± 43800 | 56300 ± 36900 |
| SFU | 33000 ± 33300 | 23800 ± 23000 | 45800 ± 28800 | 18900 ± 20800 |
Cycle length=21 days; C=Cohort; D=Day; EOT=End of Treatment; PD=predose; SFU=Safety Follow-up (up to 30 days after EOT date)
| percentage of participants | Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | Cohort 1 Group 2: NSCLC (Adenocarcinoma) | Cohort 1 Group 3: NSCLC (SCC) | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC |
|---|---|---|---|---|---|---|
| Percentage of Participants With Positive Anti-SG Antibodies | 0 | 3.0 | 3.4 | 4.7 | 2.4 | 4.7 |
Collected over All-Cause Mortality and Adverse Events: Up to 5.3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | 26/31 (83.9%) | 15/31 (48.4%) | 30/31 (96.8%) |
| Cohort 1 Group 2: NSCLC (Adenocarcinoma) | 27/34 (79.4%) | 11/34 (32.4%) | 34/34 (100%) |
| Cohort 1 Group 3: NSCLC (SCC) | 28/31 (90.3%) | 13/31 (41.9%) | 30/31 (96.8%) |
| Cohort 2: HNSCC | 35/43 (81.4%) | 13/43 (30.2%) | 43/43 (100%) |
| Cohort 3: EC | 30/41 (73.2%) | 19/41 (46.3%) | 40/41 (97.6%) |
| Cohort 4: ES-SCLC | 32/43 (74.4%) | 22/43 (51.2%) | 43/43 (100%) |
| Event | Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | Cohort 1 Group 2: NSCLC (Adenocarcinoma) | Cohort 1 Group 3: NSCLC (SCC) | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC |
|---|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 1/31 | 1/34 | 2/31 | 1/43 | 7/41 | 3/43 |
| PneumoniaInfections and infestations | 1/31 | 0/34 | 4/31 | 1/43 | 2/41 | 2/43 |
| DiarrhoeaGastrointestinal disorders | 1/31 | 1/34 | 2/31 | 0/43 | 5/41 | 0/43 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/31 | 2/34 | 3/31 | 0/43 | 0/41 | 1/43 |
| HypokalaemiaMetabolism and nutrition disorders | 0/31 | 0/34 | 0/31 | 0/43 | 3/41 | 0/43 |
| Acute kidney injuryRenal and urinary disorders | 1/31 | 0/34 | 0/31 | 0/43 | 3/41 | 0/43 |
| LeukopeniaBlood and lymphatic system disorders | 2/31 | 1/34 | 0/31 | 0/43 | 0/41 | 0/43 |
| Neutropenic colitisGastrointestinal disorders | 2/31 | 0/34 | 0/31 | 0/43 | 0/41 | 0/43 |
| DeathGeneral disorders | 2/31 | 0/34 | 0/31 | 1/43 | 2/41 | 0/43 |
| Pneumonia bacterialInfections and infestations | 0/31 | 0/34 | 2/31 | 0/43 | 0/41 | 0/43 |
| Event | Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | Cohort 1 Group 2: NSCLC (Adenocarcinoma) | Cohort 1 Group 3: NSCLC (SCC) | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC |
|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 21/31 | 17/34 | 15/31 | 20/43 | 22/41 | 33/43 |
| AlopeciaSkin and subcutaneous tissue disorders | 14/31 | 22/34 | 13/31 | 16/43 | 17/41 | 13/43 |
| FatigueGeneral disorders | 15/31 | 20/34 | 18/31 | 19/43 | 24/41 | 27/43 |
| NauseaGastrointestinal disorders | 12/31 | 20/34 | 12/31 | 20/43 | 23/41 | 17/43 |
| NeutropeniaBlood and lymphatic system disorders | 16/31 | 16/34 | 15/31 | 19/43 | 24/41 | 24/43 |
| AnemiaBlood and lymphatic system disorders | 9/31 | 12/34 | 6/31 | 13/43 | 19/41 | 13/43 |
| ConstipationGastrointestinal disorders | 11/31 | 13/34 | 11/31 | 6/43 | 15/41 | 18/43 |
| Decreased appetiteMetabolism and nutrition disorders | 8/31 | 10/34 | 11/31 | 11/43 | 3/41 | 10/43 |
| VomitingGastrointestinal disorders | 7/31 | 7/34 | 7/31 | 15/43 | 10/41 | 8/43 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 8/31 | 3/34 | 9/31 | 11/43 | 2/41 | 3/43 |
The Safety Analysis Set included all participants who received at least 1 dose of SG.
| Age, Categorical(Participants) | Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | Cohort 1 Group 2: NSCLC (Adenocarcinoma) | Cohort 1 Group 3: NSCLC (SCC) | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC | Total~(N=223) |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 16 | 16 | 14 | 32 | 15 | 17 | 110 |
| >=65 years | 15 | 18 | 17 | 11 | 26 | 26 | 113 |
| Age, Continuous(years) | Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | Cohort 1 Group 2: NSCLC (Adenocarcinoma) | Cohort 1 Group 3: NSCLC (SCC) | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC | Total~(N=223) |
|---|---|---|---|---|---|---|---|
| Mean | 65 ± 8.7 | 64 ± 10.5 | 65 ± 8.4 | 61 ± 6.8 | 66 ± 9.1 | 66 ± 8.2 | 64 ± 8.7 |
| Sex: Female, Male(Participants) | Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | Cohort 1 Group 2: NSCLC (Adenocarcinoma) | Cohort 1 Group 3: NSCLC (SCC) | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC | Total~(N=223) |
|---|---|---|---|---|---|---|---|
| Female | 15 | 19 | 8 | 10 | 41 | 23 | 116 |
| Male | 16 | 15 | 23 | 33 | 0 | 20 | 107 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | Cohort 1 Group 2: NSCLC (Adenocarcinoma) | Cohort 1 Group 3: NSCLC (SCC) | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC | Total~(N=223) |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 0 | 0 | 2 | 2 | 6 |
| Not Hispanic or Latino | 30 | 31 | 29 | 40 | 34 | 36 | 200 |
| Unknown or Not Reported | 1 | 1 | 2 | 3 | 5 | 5 | 17 |
| Race/Ethnicity, Customized(Participants) | Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | Cohort 1 Group 2: NSCLC (Adenocarcinoma) | Cohort 1 Group 3: NSCLC (SCC) | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC | Total~(N=223) |
|---|---|---|---|---|---|---|---|
| Race — White | 23 | 26 | 24 | 33 | 21 | 36 | 163 |
| Race — Black or African American | 6 | 3 | 3 | 1 | 1 | 2 | 16 |
| Race — Asian | 0 | 5 | 1 | 4 | 8 | 2 | 20 |
| Race — American Indian or Alaska Native | 0 | 0 | 0 | 2 | 2 | 0 | 4 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Race — Other or More Than One Race | 1 | 0 | 2 | 0 | 3 | 1 | 7 |
| Race — Unknow or Not Reported | 1 | 0 | 1 | 2 | 6 | 2 | 12 |
| Region of Enrollment(Participants) | Cohort 1 Group 1: NSCLC [Adenocarcinoma + SCC] | Cohort 1 Group 2: NSCLC (Adenocarcinoma) | Cohort 1 Group 3: NSCLC (SCC) | Cohort 2: HNSCC | Cohort 3: EC | Cohort 4: ES-SCLC | Total~(N=223) |
|---|---|---|---|---|---|---|---|
| United States | 31 | 32 | 26 | 34 | 28 | 22 | 173 |
| France | 0 | 0 | 3 | 5 | 2 | 2 | 12 |
| Australia | 0 | 0 | 1 | 1 | 4 | 5 | 11 |
| Hong Kong | 0 | 2 | 1 | 1 | 5 | 0 | 9 |
| Spain | 0 | 0 | 0 | 0 | 0 | 9 | 9 |
| Taiwan | 0 | 0 | 0 | 1 | 1 | 2 | 4 |
| Canada | 0 | 0 | 0 | 1 | 1 | 1 | 3 |
| Belgium | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2019 to primary completion in Jan 2025, 63 months.
Results were first posted in Jan 2026, 1 year after primary completion.
Of 88 industry-sponsored phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's 63 months is above that.
Counting every sponsor, half of 443 studies reached it within 56 months; a quarter within 33 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sacituzumab govitecan